Intervacc AB  logo

Intervacc AB (IVACC.BTA)

Delisted
XSTO XSTO
kr
kr
- Market Cap
- P/E Ratio
- Div Yield
- Volume
- Eps
kr
Previous Close
Day Range
0 0
Year Range
0 0
Want to track IVACC.BTA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.

IVACC.BTA Chart

Intervacc AB (IVACC.BTA) FAQ

What does "Delisted" mean?

Intervacc AB has been removed from the exchange and is no longer publicly traded.

What was the last recorded dividend?

No dividend payments were recorded prior to delisting.

How long did the company pay dividends?

The company did not have a dividend payment history.

Were there any stock splits?

No stock splits were recorded prior to delisting.

What was the last known trading price?

Final trading price data is not available.

Intervacc AB Profile

- Industry
- Sector
- CEO
XSTO Exchange
- ISIN
Sweden Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Intervacc AB (publ) is at the forefront of veterinary vaccine development, focusing on delivering innovative solutions for animals in Sweden. Since its inception in 1983, the company has been dedicated to addressing the critical health challenges faced by livestock and companion animals through advanced vaccine technologies. Based in Hägersten, Sweden, Intervacc AB combines scientific research with market insights to develop vaccines that not only meet the health requirements of animals but also support the needs of farmers and pet owners. Besides its strong emphasis on research and development, the company extends its expertise to the marketing and distribution of a variety of veterinary products across the Nordic markets, encompassing a range of therapeutic areas for swine, horses, cattle, and sheep.

Products and Services

  • Strangvac
  • A pioneering vaccine developed for horses to combat equine strangles, a prevalent and infectious equine disease caused by the bacterium Streptococcus equi. Strangvac represents Intervacc AB’s commitment to advancing animal health through innovative biotechnological solutions.

  • INV274
  • Targets the pressing need for effective treatment against Streptococcus suis, a significant pathogen in swine that leads to a range of health issues in piglets. INV274 comprises antigens formulated to stimulate a robust immune response, thereby offering a preventive strategy against this disease.

  • INV412
  • A multi-component vaccine designed to protect dairy cows from multiple bacteria known to cause mastitis, a major concern for the dairy industry due to its impact on milk production and animal welfare. INV412 demonstrates Intervacc AB’s multidisciplinary approach to addressing complex diseases with profound economic impacts.

Alongside its product pipeline, Intervacc AB actively participates in the Nordic veterinary market, distributing a comprehensive array of pharmaceuticals and vaccines tailored for swine, horses, cattle, and sheep. This includes not only its own developed products but also a curated selection of veterinary solutions aimed at enhancing the overall health and productivity of livestock and companion animals.

Contact Information

Address: -
Phone: -